INTRODUCTION
Red cell transfusion has an important role in the management of sickle cell disease (SCD) in both emergency and elective settings. However, because of insufficient randomised data, it is not always clear when or how to use red cell transfusion. A companion guideline, Guidelines on red cell transfusion in sickle cell disease Part I: principles and laboratory aspects, addresses the general principles of transfusion practice in SCD (Davis et al, BJH in press ). The present guideline examines current available evidence on indications for transfusion in SCD. This may not be appropriate for all clinical scenarios and clinical decisions must be based on individual patient considerations.
In both guidelines, the term sickle cell disease refers to all genotypes of the disease, and sickle cell anaemia to the homozygous state (SS).
METHODS
The writing group was selected by the British Committee for Standards in Haematology Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria are specified in the Transfusion should be considered in women with worsening anaemia or those with acute SCD complications (acute chest syndrome, stroke etc.) (Grade 1B).
Amelioration of severe disease
In selected patients with severe disease, blood transfusion can be effective in ameliorating disease, resulting in reduction in hospital bed days.
Hydroxycarbamide is recommended as first line treatment for prevention of recurrent acute chest syndrome or repeated painful episodes associated with chest syndrome (Grade 1A). Regular transfusion should be considered for patients failing this treatment or for whom hydroxycarbamide is contraindicated or not acceptable (Grade 1B).
Other indications
Transfusion is not recommended to treat steady state anaemia provided that
Hb has not fallen over a period of time to symptomatic levels (e.g. with developing chronic kidney disease) (Grade 1C).
There is no evidence that transfusion shortens the duration of a painful crisis. Where transfusion is considered for indications where there is insufficient evidence for its benefit (e.g. leg ulcers, pulmonary hypertension, end stage renal or liver disease, progressive sickle cell retinopathy), a full risk-benefit assessment should be carried out in liaison with the SHT and each case should be considered on its own merits (Grade 2C).
Transfusion is not recommended in uncomplicated painful

INDICATIONS FOR TRANSFUSION IN SICKLE CELL DISEASE
The indications for red cell transfusion in SCD range from those in which transfusion can be strongly recommended to those where its use is unproven or controversial. A case-by-case detailed analysis of risk and benefit of red cell transfusion should be undertaken for unproven or controversial indications.
The indications can be broadly categorised into conditions in which correction of anaemia is the main goal and those where reduction of sickle haemoglobin (HbS) may be more appropriate (see Table I ). In both categories, transfusion is either performed acutely, as part of the management of an acute complication of SCD, or electively for the prevention or management of disease complications. Elective transfusions may be one-off (e.g. preoperative) or be part of a long-term transfusion programme.
The decision to transfuse any patient with SCD should be taken by senior medical staff, ideally at consultant level with the appropriate experience. Long-term elective transfusions should usually be initiated by or in consultation with a specialist haemoglobinopathy team (SHT).
It should be recognised that the low steady state Hb in SCD is the result of the low oxygen affinity of haemoglobin S and is therefore not in itself an indication or transfusion.
INDICATIONS FOR EMERGENCY TRANSFUSION
Emergency transfusion with the primary aim of correcting acute anaemia
Ascertaining the cause of anaemia
Acute anaemia in SCD has been defined as a fall in haemoglobin ≥20 g/l below the steady state value (Emond, et al 1985, National Heart, Lung and Blood Institute [NHLBI] 2014) . Understanding the cause of the anaemia is essential for appropriate management. Causes broadly include: decreased haemoglobin production, sequestration and increased haemolysis. Initial assessment should include: history of recent transfusion, haemodynamic status, spleen and liver size, full blood count and reticulocyte count. Any decision to transfuse should take into consideration the likely cause, haemodynamic status and degree of anaemia relative to baseline.
Aplastic crisis
Aplastic crisis should be suspected in patients with acute exacerbation of steady state anaemia with reticulocytopenia and is usually due to infection with human erythrovirus (formerly parvovirus) B19 (Goldstein, et al 1987 , Serjeant, et al 1993 . Anaemia is usually severe with a mean fall of approximately 40 g/l below steady state values (Goldstein, et al 1987 .
Simple transfusion to steady state level is usually all that is required to maintain the oxygen carrying capacity of blood (Goldstein, et al 1987 , Serjeant, et al 1993 , SmithWhitley, et al 2004 . Spontaneous resumption of erythropoiesis tends to occur within 7-10 days of aplasia (Anderson, et al 1985) , restoring the Hb to the steady state value. Most patients will be close to spontaneous marrow recovery at the time of clinical presentation with development of reticulocytosis and recovery of Hb occurring <7 days from presentation (Serjeant, et al 1993) .
Erythrovirus B19 may occasionally present with serious and potentially lifethreatening complications, including acute splenic sequestration, ACS (Lowenthal, et al 1996 , Smith-Whitley, et al 2004 or acute neurological syndromes including stroke (Balkaran, et al 1992 , Wierenga, et al 2001 . In such cases, exchange transfusion after initial simple transfusion may be more appropriate.
Acute splenic sequestration
Acute splenic sequestration is characterised by an acute fall in Hb ≥20 g/l, reticulocytosis and sudden splenic enlargement (Emond, et al 1985) and, in severe cases, may result in circulatory failure and even death (Emond, et al 1985 , Rogers, et al 1978 . Although splenic sequestration typically occurs in the first 5 years of life before the spleen has spontaneously infarcted, it may occasionally occur later, particularly in those with milder disease such as SC disease in whom splenic infarction may not occur until later in life (Aslam, et al 2005, Roshkow and Sanders 1990) . Immediate management consists of simple transfusion to raise the Hb to steady state level (Emond, et al 1985) . Transfusion with emergency (O Rh (D) negative) or ABO-and Rh (D)-specific uncrossmatched blood may occasionally be necessary to treat shock and anaemia in extremis. In many cases, however, cautious transfusion of small red cell volumes to raise the haemoglobin to the steady state level is sufficient to reverse the process and correct hypovolaemia and anaemia. Transfusion of large volumes of red cells (to Hb levels >80 g/l) should be avoided due to the risk of hyperviscosity when sequestered red cells return to the circulation (Josephson, et al 2007 , Kinney, et al 1990 , NHLBI 2014 , Quirolo 2010 , Wanko and Telen 2005 .
All patients with previous splenic sequestration should be discussed with the SHT.
There is a high recurrence rate (Brousse, et al 2012 , Emond, et al 1985 and splenectomy is advised in patients who have recurrent episodes (two or more).
Splenectomy is not associated with an increased long-term risk of bacteraemic episodes or death (Wright, et al 1999) . Regular transfusion to maintain HbS <30%
did not reduce the risk of recurrence or need for splenectomy after splenic sequestration compared to clinical observation in a retrospective observational study (Kinney, et al 1990) .
Acute hepatic sequestration
Acute hepatic sequestration presents with acute hepatic enlargement associated with a fall in Hb ≥20 g/l and rise in the reticulocyte count. It usually responds to simple transfusion or exchange transfusion (Gutteridge, et al 1985 , Hatton, et al 1985 ; spontaneous resolution has been reported (Hatton, et al 1985) . As in acute splenic sequestration, the return of sequestered red cells into the circulation may cause acute hyperviscosity (Lee and Chu 1996) and cautious transfusion of small volumes of red cells is recommended.
Delayed haemolytic transfusion reaction (classical and hyperhaemolysis syndrome)
A delayed haemolytic transfusion reaction (DHTR) (classical or hyperhaemolysis) must be strongly suspected in patients presenting with acute anaemia with/without pain typical of vaso-occlusive crisis following a recent transfusion (King, et al 1997 , Milner, et al 1985 , Petz, et al 1997 . Hyperhaemolysis may be missed because it is assumed that the patient's symptoms are due entirely to a painful crisis. The investigation and management of these two syndromes have been described in the companion guideline, Guidelines on red cell transfusion in sickle cell disease Part I:
principles and laboratory aspects (Davies et al, BJH in press ).
All cases of DHTR and hyperhaemolysis should be discussed with the SHT both for advice on management and because of the long-term implications of alloimmunisation and risk of hyperhaemolysis recurrence.
Increased haemolysis during painful crises
Transfusion is not recommended in uncomplicated painful crises. Although Hb often drops to slightly below steady state levels, transfusion is typically not required and
Hb will return to baseline as the crisis abates. Transfusion may be indicated if there is a substantial drop in Hb from baseline (e.g. >20 g/l or Hb<50 g/l), haemodynamic compromise or concern about impending critical organ complications (see below).
Other causes of exacerbation of anaemia
An acute decline in Hb due to haemolysis is common in acute sickle complications, such as ACS (Howard, et al 2015) and acute multi-organ failure syndrome (Hassell, et al 1994) . The role of transfusion in these two syndromes is described in sections 4.2.1 and 4.2.3. Urgent transfusion is indicated for acute blood loss.
Severe anaemia during hydroxycarbamide therapy requiring transfusion is usually due to an acute intercurrent illness, such as acute splenic sequestration, aplastic crisis or ACS rather than the myelosuppressive effects of the drug (Gulbis, et al 2005 , Hankins, et al 2005a , Kinney, et al 1999 , Scott, et al 1996 , Wang, et al 2001 .
The effects of myelosuppression are usually reversible rapidly upon reduction of the dose or temporary cessation of hydroxycarbamide but full recovery may not occur for several weeks (Hankins, et al 2005a , Wang, et al 2001 .
In patients with sickle cell nephropathy, a slow decline of haemoglobin concentration occurs as the renal disease progresses and the anaemia may be severe enough to compromise cardiovascular function . 
Recommendations
Emergency transfusion with the primary aim of reducing HbS in relation to HbA
Transfusion to reduce the %HbS is indicated where there is evidence of acute critical organ complications, especially ACS and ischaemic stroke.
Acute chest syndrome (ACS)
ACS usually develops during a painful crisis and should be suspected in patients presenting with fever and/or respiratory symptoms, together with clinical signs of lung consolidation (Howard, et al 2015) . Early recognition of ACS and intervention with blood transfusion can be life-saving.
ACS can develop rapidly and progress to acute respiratory failure within a few hours.
It is advisable to plan to have blood available if early signs of ACS occur, even if other measures subsequently render transfusion unnecessary. Both simple and exchange transfusion rapidly improved oxygenation with similar efficacy in nonrandomised studies (Turner, et al 2009 , Vichinsky, et al 2000 . A simple transfusion aiming for a target Hb 100-110 g/l is effective in preventing progression to acute respiratory failure in SS patients with mild ACS if it is given early in the illness (Emre, et al 1995) and should be considered in patients with a PaO 2 <9.0 kPa on room air, but may also be needed at less severe degrees of hypoxaemia, depending on the individual patient's history and clinical features, or if the patient's oxygen requirements are increasing (Howard, et al 2015) . Exchange transfusion is recommended in patients with features of severe ACS, those who fail to respond to initial simple transfusion, or patients with a higher Hb (>90 g/l) where there is little leeway for simple transfusion (Emre, et al 1995 , Howard, et al 2015 , NHLBI 2014 .
There is no evidence as to the optimal %HbS target post-exchange transfusion. In practice, a target of <30-40% is often used, but clinicians should be guided by the clinical response (Howard, et al 2015) .
Guidelines for the diagnosis and management of ACS are available from the BCSH (Howard, et al 2015) .
Acute ischaemic stroke
The value of transfusion and the comparative effects of exchange versus simple transfusion in acute ischaemic stroke have not been evaluated in randomised trials.
Emergency exchange transfusion to reduce HbS to <30% is recommended for acute and oxygenation to the brain, thereby preventing extension of an infarct. There is evidence from a retrospective cohort study that exchange transfusion for a first overt stroke at the time of stroke presentation is associated with a lower risk of a subsequent stroke compared to simple transfusion (Hulbert, et al 2006) . It is important to avoid hypovolaemia during the procedure and to keep the posttransfusion Hb at a target of 100 g/l, as a high haematocrit associated with hyperviscosity may worsen the neurological insult.
Current pathways for acute stroke care in the UK require adult patients with suspected stroke to be admitted directly to specialist stroke units (hyperacute stroke There are currently no data to support the use of red cell transfusion either in the acute management of haemorrhagic stroke or to prevent its recurrence and it is recommended that specialist advice should be sought for individual cases.
Acute multi-organ failure syndrome
This is a severe life-threatening syndrome that may complicate a severe painful crisis. It is particularly likely to occur in patients with otherwise mild SCD and a relatively high haemoglobin concentration. The patient presents with multi-organ failure with associated fever, rapid decrements in Hb and platelet count, non-focal encephalopathy and rhabdomyolysis. The syndrome usually responds to aggressive exchange transfusion (Hassell, et al 1994) 
Mesenteric ("girdle") syndrome
This is a rare severe sequestration syndrome characterised by simultaneous or consecutive sickling and sequestration in the mesenteric vascular bed, liver and lungs (Brozovic, et al 1987) . Preceding pain in the abdomen, lumbar spine and limbs is common. Sickling in the abdomen can present with tenderness and rigidity, mimicking peritonitis and progressing to ileus, with a silent distended abdomen and dilated loops of bowel on X-ray. ACS frequently develops due to splinting of the chest wall. Acute exchange blood transfusion is indicated.
Severe sepsis
Severe sepsis often engenders a vicious circle of tissue hypoxia, acidosis and
sickling. An exchange transfusion or simple transfusion may be useful in correcting anaemia, improving microvascular blood flow, improving tissue oxygenation and the patient's overall clinical condition (Ohene-Frempong 2001)
Acute intrahepatic cholestasis
This is a rare and little understood complication that presents with extreme hyperbilirubinaemia (mainly conjugated) (Banerjee, et al 2001 , Gardner, et al 2014 , marked elevation of the alkaline phosphatase and variable rises in transaminase levels. There is a high mortality from liver failure or bleeding. There is no established treatment but exchange transfusion appears to be beneficial (Shao and Orringer 1995) .
Acute priapism
The treatment of priority in acute fulminant priapism is penile aspiration/irrigation followed by the intracavernosal injection of sympathomimetic drugs if aspiration fails to resolve the problem (Montague, et al 2003) . This initial urological intervention should not be delayed while a transfusion is arranged.
Neither simple nor exchange transfusion have been evaluated for acute management of priapism in randomised controlled trials. Small case series and literature reviews provide no evidence of amelioration of pain or duration of priapism once this has been established (McCarthy, et al 2000 , Merritt, et al 2006 . Surgical management is indicated if initial urological measures are not effective (Montague, et al 2003) . Shunt procedures for the relief of acute priapism require a general anaesthetic so that the patient may benefit from transfusion, as with other surgical procedures (Howard, et al 2013) . If patients do not respond to initial shunt procedures there may be benefit from exchange transfusion to decrease %HbS.
Local hospitals should develop referral pathways so that patients requiring specialist surgery are transferred promptly to tertiary centres. Such patients must be discussed with the SHT with regards to possible transfusion pre-operatively.
Recommendations
Transfusion is recommended in cases of acute chest syndrome with hypoxia. 
INDICATIONS FOR CHRONIC TRANSFUSION
The best data to support chronic transfusion programmes are for the primary prevention of stroke Brambilla 2005, Adams, et al 1998) and secondary prevention of silent cerebral infarcts in paediatric populations (DeBaun, et al 2014) .
There is also good evidence for the effectiveness of transfusions in preventing recurrent stroke in children , Scothorn, et al 2002 .
Chronic exchange transfusion has been utilised for a wide variety of indications, including prevention of recurrent vaso-occlusive crises and recurrent chest syndrome. In many of these circumstances there is also evidence of benefit of hydroxycarbamide therapy (Charache, et al 1995 , Thornburg, et al 2012 and chronic transfusion should only be contemplated where hydroxycarbamide is ineffective or contra-indicated.
Where chronic transfusion is initiated outside the context of paediatric stroke, the parameters to assess efficacy should be clearly documented and the risks and benefits for the patient regularly reviewed. Outcomes of chronic transfusion programmes should be regularly audited across centres. Decisions to initiate chronic transfusion should be made by the SHT.
Primary and secondary stroke prevention
Long-term red cell transfusion is the mainstay of treatment for the primary and secondary prevention of stroke due to SCD. Evidence for the efficacy of transfusion for primary stroke prevention is available only for children but the principles may be relevant for adult patients (over 16 years). Hydroxyurea (TWiTCH) trial (Ware, et al 2016) . In this randomised trial, hydroxycarbamide at maximum tolerated dose (alternative group) was compared to standard transfusions (standard group) after patients randomised to hydroxycarbamide had been slowly weaned off transfusions over 4-9 months. This trial showed that hydroxycarbamide is non-inferior to transfusions for the maintenance of TCD velocities and can be used as a substitute to help prevent primary stroke after discontinuation of initial transfusion therapy.
Primary stroke prevention in children with
Recommendations
Transfusion to maintain HbS <30% should be offered to children at high risk of 
Secondary prevention of overt stroke in children with SCD
The risk of recurrent stroke in children with SCD is very high. In a natural history study of 35 patients with a history of one or more strokes, the recurrence rate was 67% over a 9-year period, with 80% of the recurrent episodes occurring within 36 months of the initial event (Powars, et al 1978) .
There have been no randomised trials comparing the use of transfusion to no intervention for prevention of recurrent stroke in SCD. Several single centre studies (Balkaran, et al 1992 , Lusher, et al 1976 , Russell, et al 1984 , Sarnaik, et al 1979 and two multi-centre retrospective studies , Scothorn, et al 2002 all reported a clear benefit of transfusion in reducing the risk of recurrence in patients who had suffered one or more previous episodes of cerebral infarction.
In the Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) trial, a noninferiority trial that compared transfusion to HbS <30% plus chelation with hydroxycarbamide plus phlebotomy for the composite endpoint of secondary stroke prevention and improved control of iron overload, there were no cases of recurrent stroke in the transfused patients compared with 10% in the hydroxycarbamide/phlebotomy arm . The trial was closed early because even though the increased stroke risk in the hydroxycarbamide arm was within the predicted 12% rate, it was not offset by a reduction in iron overload through phlebotomy. Therefore, the authors concluded that transfusion and chelation remain a better way to manage children with sickle cell anaemia, stroke and iron overload.
Although the risk of stroke is not completely eliminated by regular transfusions (Hulbert, et al 2011 , Scothorn, et al 2002 , transfusions to maintain HbS <30% remains the recommended intervention to prevent stroke recurrence in children with SCD. There is some evidence from a small observational study that patients on transfusion programmes for secondary stroke prevention may be maintained on a less rigorous target of HbS <50% with little increased risk of stroke recurrence, provided they have been neurologically stable for at least 4 years after the initial stroke (Cohen, et al 1992) .
Recommendation
Long-term transfusion to maintain HbS <30% is recommended for the prevention of recurrent ischaemic stroke due to sickle cell disease in children (Grade 1B).
Primary stroke prevention in adults with SCD
Adults with sickle cell anaemia are at increased risk of ischaemic and haemorrhagic stroke; the risk of ischaemic stroke is highest after the age of 30 years, whereas haemorrhagic stroke is most common in the 20-29 year age group (OheneFrempong, et al 1998). TCD has not been validated in adults and there is currently no tool for systematically assessing stroke risk. Studies to evaluate the efficacy of transfusion for primary stroke prevention in defined adult SCD populations have not been undertaken. There are no studies on the management of patients who, having been on long-term transfusions for primary stroke prevention since childhood, have crossed the transition threshold and become adults. Management of such patients is a subject for individual assessment, and discussion with young adults and carers should take place concerning the benefits and risks of remaining on transfusion or substituting with hydroxycarbamide.
Secondary stroke prevention in adults with SCD
Whilst neurological events, such as TIA or seizures, may be the initial presentation of sickle cell cerebrovascular disease, adults experiencing such episodes should be fully investigated for other possible causes (e.g. atrial fibrillation, carotid artery stenosis). Data on transfusion for secondary stroke prevention in adult SCD is
limited. An observational study (Powars, et al 1978) that included some adult subjects strongly suggests that the risk of further strokes is likely to be high without 
Recommendation
Long-term transfusion to maintain HbS <30% is recommended for the prevention of recurrent ischaemic stroke due to sickle cell disease in adults (Grade 1B).
Duration of transfusions for stroke prevention
The optimal duration of transfusion is uncertain. Data from the STOP 2 trial indicated that patients who were maintained on transfusion for a follow up period of 65 months for primary stroke prevention had a 93% lower stroke risk than patients who discontinued transfusions after 30 months (Adams and Brambilla 2005) . The results of the TWiTCH trial show that hydroxycarbamide is efficacious and non-inferior to blood transfusions for primary stroke prevention in children without severe cerebral vasculopathy or prior TIA who have been on transfusion for at least a year (mean 4 years) (Ware, et al 2016) . However, the trial did not establish the optimal duration of transfusions prior to the switchover to hydroxycarbamide. Therefore, we suggest that the duration of this initial period of transfusions is assessed on a case-by-case basis.
For patients who have had a stroke, the risk of recurrent stroke is highest in the first three years after the initial event (Balkaran, et al 1992 , Powars, et al 1978 , Russell, et al 1984 , suggesting that maintaining a HbS level <30% is especially important during this period. The benefits of transfusions beyond this period are debatable. Recurrent stroke has been reported within 12 months of prospectively stopping transfusions in 5 out of 10 children who had been on a transfusion programme for as long as 9.5 years (Wang, et al 1991) . Therefore, Long-term transfusion should be offered to children and adults who have suffered a previous ischaemic stroke due to sickle cell disease (Grade 1B).
Recurrent ACS
Acute chest syndrome is a marker of SCD severity, being a risk factor for early death in SS patients >20 years , Platt, et al 1994 and 44% of patients will have recurrent episodes . Evidence suggests that chronic transfusion therapy is effective in reducing incidence and hospitalisation due to ACS (Hankins, et al 2005b , Miller, et al 2001 , Styles and Vichinsky 1994 . In the SIT trial, ACS was significantly reduced in comparison with untransfused patients with an incidence rate ratio of 0.13 (DeBaun, et al 2014) . However, given that there is a clear benefit of hydroxycarbamide for ACS prevention (Charache, et al 1995 , Thornburg, et al 2012 , transfusion should be considered only if hydroxycarbamide is ineffective or contraindicated.
Recommendation
Hydroxycarbamide is recommended as first line treatment for recurrent acute chest syndrome or repeated painful episodes. Regular transfusion should be considered for patients failing this treatment or for whom it is contraindicated (Grade 1B).
Frequent painful crises
The frequency of sickle cell painful crises is a marker of disease severity; SS patients who are admitted to hospital ≥3 times a year because of vaso-occlusive crises are at increased risk of early death (Platt, et al 1991) . Prolonged hospitalisations and high readmission rates are also associated with a higher mortality Lusardi 2005, Houston-Yu, et al 2003) .
Long-term transfusion may be of benefit in patients with recurrent painful crises. In a retrospective study, long-term blood transfusion significantly reduced the hospital admission frequency for vaso-occlusive crises from 2.20 to 0.21 per patient per year (Styles and Vichinsky 1994) . In the STOP trial, the hospital admission rate for vasoocclusive crises in chronically transfused patients was significantly less than for patients on standard care (9.7 vs. 27.1 events per 100 patient years) (Miller, et al 2001) . In the SIT trial, incidence rates of painful crises were significantly reduced by transfusion with an incidence rate ratio of 0.41 (DeBaun, et al 2014) .
However, hydroxycarbamide is very effective in reducing the rate of painful crises and ACS in both adults and children (Charache, et al 1995 , Olivieri and Vichinsky 1998 , Scott, et al 1996 and improves survival (Steinberg, et al 2003 . Therefore, hydroxycarbamide is the first line therapy for patients with frequent vaso-occlusive crises with transfusion being reserved for those who do not respond or in whom hydroxycarbamide is contraindicated.
Recommendation
Transfusion, either by simple or exchange transfusion, should be considered in patients with frequent painful episodes where hydroxycarbamide is ineffective or contraindicated (Grade 1B)
Other possible indications
Transfusion has been used in a variety of sickle cell related problems, where clinical experience or case reports/series have suggested benefit. In patients with renal disease, transfusion may be considered in end stage renal disease, in those awaiting a renal transplant and post-renal transplant (Sharpe and Thein 2014) .
Transfusion has also been used in patients undergoing liver transplantation in the peri-transplant setting (Blinder, et al 2013 , Gardner, et al 2014 . Blood transfusion in the treatment of pulmonary hypertension seems theoretically reasonable, with the aim of decreasing haemolysis and thereby nitric oxide scavenging and consequent pulmonary vasoconstriction, and has been recommended for this purpose Hambleton 2011, Machado and Gladwin 2005) .
The incidence of priapism and symptomatic avascular necrosis was significantly decreased by transfusion in the randomised SIT trial with incidence rate ratios of 0.13 and 0.22, respectively (DeBaun, et al 2014) , but its benefit in the management of patients with established disease has not been proven in randomised trials.
Transfusion has been used for other conditions including leg ulcers (Delaney, et al 2013 , Minniti, et al 2010 and progressive sickle retinopathy (Gustave, et al 2013 , McKinney, et al 2015 . In some cases the reported benefit from transfusion has seemed dramatic, but specific recommendations must await more extensive data.
Recommendation
Transfusion for indications where evidence is limited should be based on a case-by-case assessment after full risk-benefit analysis (Grade 2C).
PREOPERATIVE TRANSFUSION
Anaesthesia and surgery increase sickle-related complications, particularly ACS, while transfusion reduces the risk of perioperative complications (Howard, et al 2013 . Meticulous attention should be paid to optimising all aspects of perioperative care including oxygenation, hydration and warmth, as well as anaesthetic and surgical technique. Close liaison between anaesthetist, surgeon and haematologist is essential to ensuring good outcomes. Complicated surgical procedures should be undertaken in centres where there is specialist haemoglobinopathy support.
With regards to transfusion, the two key questions to consider are:
1. Should SCD patients be transfused routinely preoperatively?
If transfused, what is the optimal regimen?
Role of routine preoperative transfusion
This has long been controversial with insufficient randomised trial data impacting on variability in practice across hospitals in England (Buck, et al 2005) and in other studies (Table II) . There have been advocates both of routine pre-operative transfusion (Bhattacharyya, et al 1993 , Derkay, et al 1991 , Fullerton, et al 1981 , Janik and Seeler 1980 and selective transfusion (Bischoff, et al 1988 , Fu, et al 2005 , Griffin and Buchanan 1993 , Homi, et al 1979 , Leff, et al 2007 , Oduro and Searle 1972 . A large observational study showed that perioperative transfusion was associated with a significantly lower rate of SCD-related postoperative complications for SS patients undergoing low-risk procedures and for SC patients at all surgical risk levels . However, these findings suggested that not all patients should routinely be transfused preoperatively. Another study showed that those receiving "no transfusion" suffered the highest overall SCD-related complication rate (32%), chest syndrome rate (19%) and mortality rate (5%) but without significant difference between those randomised to aggressive or simple transfusion regimens (Haberkern, et al 1997) The most compelling evidence to support preoperative transfusion comes from the Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) trial (Howard, et al 2013) . This was a randomised controlled trial in which a total of 67 SS and Sβ o thalassaemia patients undergoing low risk surgery (e.g. adenoidectomy, dental procedures) and medium risk surgery (e.g. joint replacement, cholecystectomy, tonsillectomy) were randomly assigned to either no transfusion or transfusion (simple transfusion if Hb <90 g/l, exchange transfusion if Hb ≥90 g/l to achieve estimated HbS <60%) (Howard, et al 2013) . Classification of surgical risk was in accordance with the Cooperative Study of Sickle Cell Disease criteria .. Significantly greater clinically important complications (39% vs. 15%) and serious adverse events (30% vs. 3%) were found in untransfused SS and S/β othalassaemia compared to transfused patients undergoing low-risk and medium-risk surgery. The most common serious adverse event was ACS, accounting for 91% of all serious events occurring in 27% of untransfused patients compared with 3% in transfused patients. Intraoperative or postoperative transfusion was increased in the patients who had not been transfused preoperatively (Howard, et al 2013) .
Although the final number of subjects recruited into the trial at its termination was small, the TAPS study provided clear evidence to support preoperative transfusion in SS patients undergoing low-and medium-risk surgical procedures.
Optimal preoperative transfusion regimen
In a study of SS and S/β o -thalassaemia patients , a top-up transfusion regimen to haemoglobin 100 g/l was reported to be as effective as exchange transfusion to attain haemoglobin 100 g/l and HbS <30% in preventing perioperative complications and was associated with a 50% lower risk of transfusionrelated complications. However, it must be noted that the type of exchange transfusion procedure was not described and some of the exchange transfused patients required repeated simple transfusion. Furthermore, in 14% of patients in the exchange transfusion arm, post-transfusion %HbS was substantially higher than the 30% target for a number of reasons including inadequate transfusion. Moreover, in the simple transfusion group, nearly 43% of the patients received "minimal transfusion therapy". Despite these limitations, the authors concluded that simple transfusion was as effective as exchange transfusion.
The issue of whether simple or aggressive transfusion had better outcomes was not addressed in the TAPS trial, where the transfusion regimen was either simple transfusion if Hb <90 g/l or partial exchange transfusion if Hb ≥90 g/l, to a target Hb of 100 g/l and estimated HbS <60% (Howard, et al 2013) . Seventy-six per cent of transfused patients received simple transfusion, providing support for the efficacy of a conservative transfusion regimen in reducing post-operative complications for the relevant surgical procedures reported in the trial.
It is not possible to give dogmatic guidelines regarding the choice of type of preoperative transfusion and transfusion targets; these should be tailored to the individual patient, taking into account factors such as the type of surgery, the severity of the patient's SCD and co-morbidities (see section 6.5, Role of transfusion in surgery for sickle genotypes other than SS). However, it is reasonable to undertake simple transfusion for low and moderate risk surgery if Hb is <90 g/l to achieve a post-transfusion Hb of 100 g/l. An exchange transfusion should be considered for patients undergoing high-risk surgery, patients with severe SCD and those with significant co-morbidities.
Emergency surgery
Evidence for the role of transfusion in emergency surgery is very limited. In the largest study on surgery in SCD, 717 patients underwent 1079 surgical procedures of which 271 (25%) were emergency procedures . When all procedures (elective + emergency) were considered, most patients undergoing cholecystectomy and splenectomy were transfused preoperatively (94% of SS and 82% of SC) as were those undergoing Caesarean section or hysterectomy (91% of SS and 72% of SC). As the data for postoperative outcomes were analysed together for elective and emergency procedures (rather than separately), it is not possible to assess the effect on transfusion on outcomes for SCD patients undergoing emergency surgery in this study.
Similarly, in another observational study, no separate analyses were carried for patients undergoing emergency surgery (Bischoff, et al 1988) . In a further retrospective study where perioperative transfusion was used selectively and sparingly (Homi, et al 1979) , 5 postoperative deaths occurred in 28 patients undergoing emergency surgery; however, it is not clear if these patients were transfused preoperatively.
The important principle here is to not unnecessarily delay emergency surgery because of transfusion. A reasonable policy is to give a simple transfusion to patients who have Hb <90 g/l and then proceed to surgery with minimal delay. If the Hb is >90 g/l and the surgical procedure is low risk, it is reasonable to proceed to surgery without delay while arrangements are made to transfuse the patient intraoperatively or post-operatively if necessary.
Role of transfusion in surgery for sickle genotypes other than SS
There is a paucity of evidence relating specifically to SC and other sickle genotypes.
One observational study suggested a benefit for transfusion in reducing the incidence of sickle cell-related postoperative complications for SC patients at all levels of surgical risk , however, transfused SC patients undergoing low-risk surgery had higher rates of non-sickle cell postoperative complications (fever and bleeding) than untransfused patients. A further study demonstrated that preoperative transfusion was beneficial for moderate risk procedures, particularly abdominal surgery (Neumayr, et al 1998) .
6.5 Deciding which patients may benefit from preoperative transfusion.
The TAPS trial has provided evidence for the efficacy of preoperative transfusion only for SS patients with preoperative Hb 60-90 g/l undergoing a narrow range of elective medium-risk surgical procedures (Howard, et al 2013) . The trial's findings may not be applicable to many other surgical situations. However, on the basis of the findings, it is recommended that preoperative transfusion to an Hb of 100 g/l be considered a standard intervention in SS undergoing elective low-risk or medium-risk surgery as defined in the study (Howard, et al 2013) . For other patients it is recommended that each case is judged on its own merits in consultation with the SHT. Transfusion should be considered when the risk of post-operative chest infection or ACS is high, but this has yet to be clearly shown in prospective trials.
Transfusion is also recommended for individuals with significant co-morbidities (e.g. abnormal pulmonary, cardiac, renal and hepatic function) and in those undergoing high-risk surgical procedures or having lengthy surgical procedures (Wun & Hassell 2009 ).
The optimal method of transfusion remains an open question but currently available evidence indicates that simple transfusion is not inferior to exchange transfusion in low-to medium-risk surgery (Howard, et al 2013 , However exchange transfusion is recommended for patients undergoing high-risk surgery, although this has not been directly addressed in studies. 
Recommendation
TRANSFUSION IN PREGNANCY
Sickle cell disease in pregnancy is associated with an increased risk of both maternal and fetal complications (Oteng-Ntim, et al 2015a , Oteng-Ntim, et al 2015b , Serjeant, et al 2004 , Smith, et al 1996 , Villers, et al 2008 . Maternal complications include sickle-related problems (notably painful crises, ACS) and pregnancy-related syndromes, such as pre-eclampsia, pre-term labour and an increased rate of Caesarean section (Oteng-Ntim, et al 2015b , Villers, et al 2008 . Fetal complications include intra-uterine growth restriction, prematurity and increased rates of fetal loss (Oteng-Ntim, et al 2015b, Serjeant, et al 2004) . In a UK-wide observational study of 109 pregnancies in SCD, 52% of women suffered painful crises during pregnancy and 13% within six weeks post-partum; 6% had ACS and 21% were admitted to intensive care (Oteng-Ntim, et al 2015a).
There is a single prospective randomised controlled study that compared 36 pregnant SS women who were transfused prophylactically (simple or partial exchange transfusion commencing in the first or second trimester; target Hb 100-110 g/l; target HbS <35%) to a control group of 36 SS women who received transfusion only for medical or obstetric emergencies (Koshy, et al 1988) . This study found a significant reduction in the incidence of painful crises and substantial decrease in other SCD-related complications in the group receiving prophylactic transfusions but no difference in medical and obstetric complications or fetal outcome between the two groups. Additionally, satisfactory pregnancy outcomes were observed in a nonrandomised group of SS, SC and S/β thalassaemia women who were transfused only for medical or obstetric emergencies. In view of these results, the authors concluded that omitting prophylactic transfusions was not harmful to pregnant patients with SCD or their offspring and thus routine use of transfusions in pregnancy was not justified. However, this study had a number of significant limitations including small sample size and high risk of bias (Malinowski, et al 2015) .
Other uncontrolled studies have shown conflicting evidence, with some showing evidence for a benefit of transfusion (Asma, et al 2015 , Benites, et al 2016 , Cunningham, et al 1983 , Gilli, et al 2007 , Howard, et al 1995 , Morrison, et al 1991 whilst others did not (El-Shafei, et al 1995 , Tuck, et al 1987 . The study by Howard et al (1995) demonstrated a trend for reduced SCD-related complications in the third trimester in patients on prophylactic exchange transfusions, leading the authors to recommend prophylactic transfusions from the 26 th week of pregnancy onwards in SS patients. In a more recent retrospective study, high rates of painful sickle crises and other severe sickle complications occurred despite a policy of prophylactic partial exchange transfusions to maintain HbS <40% from 22-26 weeks onwards for all sickle patients (Ngo, et al 2010) , but there was no control arm not receiving prophylactic transfusion for comparison.
A Cochrane review which examined evidence from two small studies of low quality concluded that other than a marginal reduction in the rate of painful crises, prophylactic transfusion conferred no clear advantage over selective transfusion with regards to pregnancy outcome (Okusanya and Oladapo 2013) . However, the findings of a more recent systematic review and meta-analysis, which included 11 cohort studies and the RCT reported by Koshy et al (1988) , suggested that prophylactic transfusion is associated with a reduction in vaso-occlusive episodes, maternal mortality, overall pulmonary complications, neonatal mortality and pre-term birth while acknowledging the methodological limitations of the original study designs (Malinowski, et al 2015) .
As a result of the limited and sometimes conflicting data, the use of prophylactic transfusion varies between centres. There is a consensus however that pregnant women with a history of severe SCD-related complications, such as recurrent ACS and stroke, individuals on chronic transfusion prior to pregnancy, and those with repeated sickle cell crises or exacerbation of anaemia during pregnancy, should receive transfusion (Koshy 1995 2007, Koshy 1995 , RCOG 2011 .
It should be emphasised that pregnancy in women with SCD is high-risk and expert obstetric care is essential to achieving good outcomes. The ideal standard of care is joint management by obstetricians and haematologists who are experienced in the care of SCD patients.
Recommendations
Prophylactic transfusion is not routinely required for sickle pregnancy, but should be considered for women with:
• previous or current medical, obstetric or fetal problems, related to SCD
• women previously on hydroxycarbamide because of severe disease
• multiple pregnancy (Grade 1C).
Women on long-term transfusions for stroke prevention or for amelioration of severe sickle complications should continue with regular transfusions throughout pregnancy. (Grade 1B).
Transfusion should be considered in women with worsening anaemia or those with acute SCD complications (acute chest syndrome, stroke etc.) (Grade 1B).
Date for guideline review
This guideline will be reviewed within 5 years of completion of the final draft.
Disclaimer:
While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, the authors, the British Society for
Haematology nor the publishers accept any legal responsibility for the content of these guidelines.
